GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Shares Outstanding (EOP)

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Shares Outstanding (EOP) : 30.74 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Comera Life Sciences Holdings's shares outstanding for the quarter that ended in Sep. 2023 was 30.74 Mil.

Comera Life Sciences Holdings's quarterly shares outstanding increased from Jun. 2023 (19.16 Mil) to Sep. 2023 (30.74 Mil). It means Comera Life Sciences Holdings issued new shares from Jun. 2023 to Sep. 2023 .

Comera Life Sciences Holdings's annual shares outstanding declined from Dec. 2021 (19.09 Mil) to Dec. 2022 (16.71 Mil). It means Comera Life Sciences Holdings bought back shares from Dec. 2021 to Dec. 2022 .


Comera Life Sciences Holdings Shares Outstanding (EOP) Historical Data

The historical data trend for Comera Life Sciences Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Shares Outstanding (EOP) Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Shares Outstanding (EOP)
19.09 19.09 16.71

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 16.65 16.71 22.30 19.16 30.74

Competitive Comparison of Comera Life Sciences Holdings's Shares Outstanding (EOP)

For the Biotechnology subindustry, Comera Life Sciences Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Shares Outstanding (EOP) falls into.



Comera Life Sciences Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Comera Life Sciences Holdings  (OTCPK:CMRA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Comera Life Sciences Holdings Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065